摘要
对正常人、良恶性肝病及肝脏以外恶性肿瘤、糖尿病、孕妇等３３８例临床样本的血清α－Ｌ－岩藻糖苷酶（ＡＦＵ）的测定结果显示：原发性肝癌（ＰＨＣ）组ＡＦＵ明显高于正常组和其它各组（Ｆ＝１１．６９８３，Ｐ＜０．０１）；在ＰＨＣ组甲胎蛋白（ＡＦＰ）阳性或阴性病例中，与ＡＦＵ阳性率无相关性（Ｘ２＝２．７２，Ｐ＞０．０５），提示ＡＦＵ与ＡＦＰ一样，对ＰＨＣ的诊断有重要价值，尤其对ＡＦＰ阴性或低滴度阳性的ＰＨＣ意义更大。此外，ＡＦＵ与ＡＦＰ联合检测，可提高ＰＨＣ的检出率；ＡＦＵ还可对ＰＨＣ的临床疗效作出评估。
Serumα-L-fucosidase(AFU)was determined in 338 cases,including 47 cases of primary hepatic carcinoma(PHC),83 various liver diseases,29 gastrointestinal tumors,5 non-gastrointestinal tumors,39 diabetes,78 pregnancy,and 57 healthy controls.The results showed that AFU was significantly higher in PHC than in the controls and other diseases P<0. 01).As a biochemical marker,AFU was useful in the diagnosis of PHC with a sensitivity of 76.5% and specificity of 84.2%. The diagnostic positivity of AFU was 68. 4%in PHC patients with normal or low AFP level.By combining AFU with AFP,the diagnostic positivity of PHC was raised to 87. 2%.These findings suggest the AFU level may be of value in the early detection of PHC as well as in the follow-up of PHC patients.
